Product Description
selective EZH2 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31471312/)
Mechanisms of Action: EZH2 Inhibitor,EED Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Multiple Myeloma|Follicular Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT02082977 | P1 |
Terminated |
Multiple Myeloma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma |
2017-06-20 |
2019-03-20 |
Treatments |